Clinical Trial Results:
A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon
Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis
C Genotype 1 and 4 Infection
Revised Protocol Number 03, incorporating amendments 03, 04 and 05
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 16-Apr-10)
Summary
|
|
EudraCT number |
2010-018295-24 |
Trial protocol |
SE DE FR IT DK |
Global completion date |
29 Aug 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
AI444-010_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.